“PXS‐5505 is currently progressing well through a phase 1c/2 clinical trial looking for evidence of disease modifying effects in bone cancer myelofibrosis as a monotherapy. Exploring the potential of PXS‐5505 to address liver cancers such as cholangiocarcinoma or other cancers where fibrosis is limiting the clinical benefit of current chemotherapy is something we will continue to assess with our scientific and clinical collaborators.”
The phase 1c/2a trial MF‐101 in myelofibrosis, cleared by the FDA under the Investigational New Drug (IND) scheme, aims to demonstrate that PXS‐5505 is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment with approved Page 1 of 3JAK inhibitor drugs.
An effective pan‐LOX inhibitor for myelofibrosis would open a market that is conservatively estimated at US$1 billion per annum.
PXS Price at posting:
9.5¢ Sentiment: None Disclosure: Held
